Business Context and Reporting Period
Company: Matinas BioPharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 9, 2024
Reporting Period: Quarter ended March 31, 2024
This filing serves as a notification that the Company issued a press release on May 9, 2024, announcing its financial results for the first quarter of 2024. The full text of the press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are detailed in the body of this Form 8-K. The document solely references the issuance of the Q1 2024 results.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing management's discussion of the quarter's results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2024) for specific Q1 2024 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of any outstanding debt or financing activities referenced in the full report.